A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
95
Theravance Biopharma Investigational Site
Pasadena, California, United States
Safety and tolerability of TD-1211
Time frame: 14 days
Complete spontaneous bowel movements (CSBM); Spontaneous bowel movements (SBM)
Change from baseline in the weekly SBM and CSBM frequency
Time frame: Weekly assessments throughout Treatment Period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.